Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by B. Riley
Research analysts at B. Riley assumed coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) in a note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $85.00 price target on the biopharmaceutical company’s stock. B. Riley’s price objective would suggest a potential upside of 93.71% from […]
More Stories
MFS Government Markets Income Trust (NYSE:MGF) Increases Dividend to $0.02 Per Share
MFS Government Markets Income Trust (NYSE:MGF – Get Free Report) declared a monthly dividend on Tuesday, October 1st, Wall Street...
Eaton Vance California Municipal Bond Fund (NYSE:EVM) Declares Monthly Dividend of $0.04
Eaton Vance California Municipal Bond Fund (NYSE:EVM – Get Free Report) announced a monthly dividend on Tuesday, October 1st, Wall...
Nuveen New York Select Tax-Free Income Portfolio (NXN) To Go Ex-Dividend on October 15th
Nuveen New York Select Tax-Free Income Portfolio (NYSE:NXN – Get Free Report) declared a monthly dividend on Tuesday, October 1st,...
Nuveen Select Tax-Free Income Portfolio Announces Monthly Dividend of $0.05 (NYSE:NXP)
Nuveen Select Tax-Free Income Portfolio (NYSE:NXP – Get Free Report) announced a monthly dividend on Tuesday, October 1st, Wall Street...
US Layoffs Up 53 Percent in September From Previous Year
By Andrew Moran New data show that employers handed out fewer pink slips in September than in August, when the...
Popular Weight Loss Drugs No Longer in Shortage; FDA to Limit Cheaper Alternatives
By Chase Smith The FDA has officially removed popular weight loss drugs, including Lilly’s Mounjaro and Zepbound, from its drug...